Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
Alterome Therapeutics, Inc.
Xencor, Inc.
Boehringer Ingelheim
ViroMissile, Inc.
Replimune Inc.
Pfizer
Pfizer
Tizona Therapeutics, Inc
National Institutes of Health Clinical Center (CC)
Baylor College of Medicine
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Revolution Medicines, Inc.
Pheon Therapeutics
SystImmune Inc.
Pheon Therapeutics
National Cancer Institute (NCI)
Eli Lilly and Company
Seagen Inc.
AgonOx, Inc.
Novartis
Seagen Inc.
Shanghai Juncell Therapeutics
University Health Network, Toronto
National Cancer Institute (NCI)
AstraZeneca
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
National Institutes of Health Clinical Center (CC)
Sanofi
Revolution Medicines, Inc.
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
Novita Pharmaceuticals, Inc.
Anhui Provincial Hospital
Trishula Therapeutics, Inc.
Nuvation Bio Inc.
Compugen Ltd
Monopar Therapeutics
Monopar Therapeutics
Columbia University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University of California, Davis